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Purpose: Oral mucositis is a significant toxicity of cytotoxic chemo- and radiation-therapy 
used to treat cancer. Palifermin is the first pharmaceutical/biological agent approved for the 
intervention of oral mucositis. The major objective of this review is to evaluate the evidence 
supporting the use of palifermin.
Methods: A literature search was performed using an appropriate keyword search in MEDLINE 
and PubMed databases.
Results: Of 100 full papers and 4 abstracts identified, 12 papers and 3 abstracts were appro-
priate for analysis. Level 2 evidence supporting palifermin use in patients with hematologic 
malignancies being treated with autologous hematopoietic stem cell transplantation (HSCT) is 
clear. Level 2 evidence also exists for the use of palifermin in the prevention of oral mucositis 
in patients with solid tumors (colorectal cancer, head and neck cancer), but is incomplete. 
Level  3 data support the use of palifermin in allogeneic HSCT recipients and cycled chemo-
therapy. A single health economic study concluded that palifermin is essentially cost neutral in 
the autologous HSCT population.
Conclusion: Data supporting the use of palifermin in autologous HSCT recipients with hema-
tologic malignancies is clear. Some data exist demonstrating its efficacy in other oncologic 
indications. Additional studies are needed to broaden the potential applications of palifermin 
and to ascertain its economic, but not symptomatic, effectiveness.
Keywords: oral mucositis, palifermin, toxicity
Core evidence proof of concept summary for palifermin in the amelioration of 
oral mucositis
Outcome measure Evidence Implications
Patient-oriented evidence
reduced incidence of severe oral mucositis 
in autologous HSCT recipients
Clear reduced need for opioid analgesics
reduced duration of severe oral mucositis in 
autologous HSCT recipients
Clear reduced need for opioid analgesics
reduced risk of febrile neutro-
penia
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Scopes, aims, and objectives
Oral mucositis is a significant and common toxicity of both 
drug and radiation therapy used for the treatment of many 
cancers. In some cases, its severity limits patients’ ability to 
tolerate and continue cancer therapy. The lack of an effective 
intervention has frustrated patients and their healthcare pro-
viders since the advent of cytotoxic cancer treatment. Recently 
palifermin (Kepivance®) became the first pharmaceutical/
biological approved for the treatment of mucositis, although 
in a small segment of the at risk population. The main objec-
tive of this article is to evaluate the evidence supporting 
the use of palifermin for its approved indication in patients 
undergoing hematopoietic stem cell transplantation (HSCT) 
for hematologic maligancies, and for other populations at risk 
of oral mucositis. Additional discussion will assess studies 
assessing the cost-effectiveness of palifermin.
Methods
Data were obtained with an online search strategy of MED-
LINE and PubMed databases using the following search 
terms: ‘palifermin’, ‘keratinocyte growth factor (KGF)’, 
and ‘mucositis’. In addition, meeting abstracts for American 
Society of Clinical Oncology (ASCO) and American Society 
for Therapeutic Radiology and Oncology (ASTRO) were 
searched using the keywords ‘mucositis’ and ‘palifermin’.
The selection of papers and abstracts for inclusion was 
limited to human clinical trials. Reviews and pre-clinical 
studies were excluded.
Disease overview
Oral mucositis is a common, painful, debilitating toxicity 
of many forms of chemotherapy and radiation to the head 
and neck.1 The condition results in a continuum of clinical 
changes that range from erythema and burning of the oral 
and oropharyngeal mucosa to the development of diffuse and 
confluent ulcerations. The latter are often of such severity 
as to require opioids to manage pain, inhibit eating or drink-
ing so necessitating parenteral nutrition, cause unscheduled 
office and emergency room visits, and hospital admission 
for fluid support. In patients who are myeloablated, mucosal 
ulcerations result in a conduit for oral bacteria to enter the 
bloodstream and cause bacteremia and sepsis. Because of its 
(Continued)
Outcome measure Evidence Implications
reduced incidence of ulcerative oral 
mucositis in allogeneic HSCT recipients
Some As above
reduced duration of ulcerative oral 
mucositis in allogeneic HSCT recipients
Some As above
reduced incidence of ulcerative oral 
mucositis in patients receiving cycled 
chemotherapy




reduced time to onset, duration, and 
incidence of ulcerative oral mucositis in 
patients receiving chemoradiation for 
cancers of the head and neck
Some reduced breaks in radiotherapy or 
chemotherapy
reduced analgesic use
reduced reliance on gastrostomy 
tube feedings
Fewer unplanned office and 
emergency room visits and 
hospital admission
Economic evidence
Cost-effective in reducing costs associated 
with mucositis-associated complications in 
autologous
reduction in mucositis-associated 
adverse outcomes offset cost of 
palifermin. 
HSCT recipients Nonsignificant savings (US$3,595) 
per patient
Abbreviations: HSCT, hematopoietic stem cell transplantation.Core Evidence 2009:4 201
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severity, mucositis is a common reason for compromising 
modifications in dosing or treatment schedules which 
adversely impact tumor outcome.
The incidence and severity of mucositis is determined by 
a number of factors including cancer diagnosis, drug choice 
and dose, drug or radiation schedule, patient age, body mass, 
and gender, and a range of genetic factors. Among patients 
being treated with concomitant chemoradiation for cancers of 
the head and neck, the incidence of severe mucositis exceeds 
50%. Almost all patients being treated for cancers of the 
mouth and oropharynx will develop severe ulcerative lesions. 
Patients receiving aggressive myeloablative chemotherapy as 
part of conditioning regimens preceding HSCT, especially 
regimens in which total body irradiation (TBI) is given are 
also at particularly high (50%) risk of severe mucositis.
Mucositis risk varies among patients with colorectal 
or breast cancers who receive multicycle chemotherapy. 
Although the reported cycle 1 incidence varies, about 20% 
of patients being treated with commonly used chemotherapy 
regimens for either of the above cancers reportedly develop 
ulcerative oral mucositis. This risk increases with subsequent 
cycles if no adjustment in dose (dose de-escalation) is made.
It is noteworthy that the incidence and severity of oral 
mucositis, like the majority of toxicities, is underreported. 
This discrepancy was clearly illustrated in the results of a 
recent study of colorectal patients in which over 70% of 
patients reported symptoms of mucositis, a much higher 
number than expected based on literature reports.2
It has been estimated that there will be about 450,000 
patients affected by oral mucositis in the United States this 
year. The incremental cost of the condition appears to be sig-
nificant. Among a population of patients with non-small cell 
lung or head and neck cancers, Nonzee and colleagues reported 
a differential cost between patients with mucositis compared 
to those without the condition of US$18,515 (US$39,313 with 
mucositis vs $20798 without mucositis).3 As noted by Sonis 
and colleagues, a similar trend was seen in patients receiving 
HSCT where an increase in mucositis severity as expressed 
by a one-point change in mucositis score was associated with 
US$25,405 in additional hospital charges.4
Current therapy options
Despite its severity and tenure, there are few approved treatment 
options for mucositis. In the United States, palifermin is the only 
approved intervention and it is solely indicated for patients with 
hematological malignancies receiving conditioning regimens 
in preparation for HSCT. Current evidence-based treatment 
approaches are delineated in the clinical practice guidelines 
produced by Multinational Association of Supportive Care 
in Cancer (MASCC) and published in 2007.5 The panel’s 
recommendations include strategies aimed at reducing the risk 
of oral mucositis by the practice of basic oral care, aggressive 
pain management for oral mucositis using morphine, and use 
of radiation techniques that minimize mucosal injury. Oral 
cryotherapy prior to administration of specific forms of che-
motherapy was endorsed. Benzydamine HCl (not available in 
the United States) was recommended for patients undergoing 
radiation therapy for cancers of the head and neck. Palifermin, 
60 µg/kg for three days prior to conditioning treatment and for 
three days post-transplantation was recommended for patients 
receiving high-dose chemotherapy with total body irradiation 
in preparation for autologous HSCT.
Although not included in the MASCC guidelines, 
the use of ‘magic mouthwashes’ for the treatment of oral 
mucositis is common.6 ‘Magic mouthwashes’ encompass a 
range of palliative solutions that are locally formulated and 
largely ineffective.7 While there is no uniformity in their 
composition, typically they include a mucoadherent vehicle 
such as milk of magnesia or Maalox® and a topical anesthetic 
such as lidocaine or Benadryl®. In addition, some include 
antifungal agents, steroids, and antibiotics. Typically the 
ingredients are based on institutional folklore as data sup-
porting the efficacy of these solutions or their superiority 
over saline or bicarbonate rinses are lacking.
Another palliative alternative for patients with mucositis 
are those that fall into the device category. Barrier agents 
such a GelClair® and Mucotrol® are self-applied by patients 
in an attempt to cover ulcerated mucosa and reduce symp-
toms. Alternatively, a modified saline solution developed for 
remineralizing teeth in patients with xerostomia (Caphosol®) 
has also received approval as a device for mucositis. Studies 
supporting the use of these agents are sparse.
Relative to palifermin, two similar molecules, both in the 
fibroblast growth factor (FGF) super class, have been tested 
clinically: KGF-2 and FGF-20. In a phase I/II randomized, 
double-blind, placebo-controlled, multi-institutional study, 
Repifermin (KGF-2) significantly reduced the incidence of 
ulcerative mucositis in patients receiving mucotoxic chemo-
therapy as part of a conditioning regimen prior to autologous 
HSCT.8 The study was sponsored by Human Genome Sciences, 
which has since ceased development of Rapifermin.
In 2005, CuraGen reported that subjects who received a 
single 0.03 mg/kg dose of velafermin (FGF-20) a reduced 
incidence of severe oral mucositis compared to those 
receiving placebo. The study, performed in patients receiving 
high-dose chemotherapy with or without total body irradiation Core Evidence 2009:4 202
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in preparation for autologous HSCT, failed to meet its primary 
endpoint as evaluated by predefined dose trend analysis. 
CuraGen did not continue development of the molecule.
Unmet need
Oral mucositis is a clinically significant, burdensome toxic-
ity of both head and neck radiation treatment and systemic 
chemotherapy. Currently an approved, effective intervention 
is available for only 4% of the at-risk population.
Clinical studies with palifermin
Palifermin has been tested in randomized, double-blind, 
multi-institutional studies as an intervention for oral muco-
sitis in three clinical settings: 1. conditioning regimens 
associated with autologous and allogeneic HSCT in patients 
with diagnosed hematologic malignancies; 2. cycled chemo-
therapy for the treatment of solid tumors (colorectal cancers); 
and 3. Radiation therapy with concomitant chemotherapy for 
the treatment of cancers of the head and neck.
HSCT
The most supportive study for palifermin’s efficacy as an 
intervention among patients receiving mucotoxic condi-
tioning regimens prior to HSCT is provided by Spielberger 
and colleagues.9 In this multicenter, double-blind, random-
ized, placebo-controlled trial of 212 autologous transplant 
recipients, palifermin was noted to: 1. reduce the incidence 
of severe (WHO grades 3, 4) mucositis from 98% in placebo-
treated subjects to 63% in those receiving six doses (60 µg/kg, 
three doses prior to the start of conditioning and three doses 
following transplant) of palifermin (p  0.001); 2. reduce 
the median duration of WHO grades 3, 4 mucositis from 
nine days to three days (p  0.001); 3. reduce the incidence 
of WHO grade 4 mucositis from 62% to 20% (p  0.001); 
and 4. significantly reduce patient reported mouth pain, opiod 
use, and use of total parenteral nutrition.
Two studies compared palifermin efficacy to retrospective 
controls. In a multicenter study Nasilowska-Adamska and 
colleagues10 assessed the efficacy of palifermin in prevent-
ing oral mucositis in 53 patients who received conditioning 
regimens prior to either autologous or allogeneic HSCT. The 
response to palifermin was compared to a similarly sized, 
retrospective population matched for age, gender, diagnosis, 
disease state, and HSCT type. Unlike the Spielberger trial, sub-
jects were being treated for both malignant and nonmalignant 
disease. Patients who received allogeneic HSCT received 
prophylaxis for graft-versus-host disease that included 
methotrexate. Palifermin was administered in the same dose 
and schedule as described by Spielberger.9 The investigators 
reported that the incidence of WHO grades 1–4 was 58% in 
the palifermin-treated population compared to 94% in the 
retrospective controls (p  0.001). The mean duration of all 
grades of mucositis was four days in the palifermin group ver-
sus nine days in the control group (p  0.001). The population 
treated with palifermin used less analgesics, including opiods, 
and total parenteral nutrition (both p  0.001).
In a second, multi-institutional unblinded trial in which 
palifermin was compared to retrospective controls, Langner 
and colleagues11 reported their findings in 30 patients under-
going allogeneic HSCT for treatment of leukemia. Palifermin 
was administered using the same dosing regimen as described 
by Spielberger.9 The majority of subjects received a highly 
mucotoxic conditioning regimen consisting of cytoxan and 
total body irradiation (TBI). Consistent with the earlier 
reports, the incidence of ulcerative mucositis (WHO 
grades 2–4) was less in palifermin-treated patients (60%), 
compared to the retrospective control group (86%; p  0.04). 
While palifermin appeared to confer an advantage in reducing 
the incidence of more severe (WHO grades 3, 4) mucositis, 
the difference observed (controls 53%, palifermin 37%) was 
not significant (p = 0.19). In contrast, the mean duration of 
mucositis was significantly less when the two populations 
were compared (controls 12 days, palifermin six days, 
p  0.003). Both opioid and TPN use were significantly less 
in palifermin-treated subjects.
The results of three single center studies have also been 
reported. Horsley and colleagues12 reported that palifermin 
administered using the Spielberger-reported regimen to 
32 patients undergoing HSCT was beneficial against muco-
sitis compared to a 27 subject retrospective population. In 
contrast to the daily mucositis assessment performed in other 
trials, Horsley’s group evaluated mucositis at a single time 
point (day 8) where they found that the incidence of severe 
mucositis (13%) was less than noted in the historical controls 
(48%; p = 0.003). They also noted that palifermin favorably 
affected swallowing problems, nutrition impact symptoms, 
and hospital length of stay.
Also using a historical control, Rzepecki and colleagues13 
found that patients receiving conditioning chemotherapy 
regimens prior to both autologous (n = 11) or allogeneic (n = 9) 
HSCT as treatment for hematologic malignancies benefited 
from palifermin treatment. They did not observe a single case 
of ulcerative mucositis, whereas the condition was noted in 
50% of a retrospective control population had severe mucositis, 
typically lasting between 10 and 12 days. The palifermin cohort 
required fewer analgesics and days of antibiotics.Core Evidence 2009:4 203
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In a report of the first five HSCT patients to receive 
palifermin at the Royal Adelaide Hospital, Keefe and 
colleagues14 found severe (WHO grade 4) mucositis in two 
subjects and WHO grade 2 in the remaining three. Duration 
of severe mucositis ranged from six days in one subject to 
12 days in the other.
Cycled chemotherapy
Palifermin has been studied in multicenter, double blind, 
placebo-controlled, randomized trials in patients receiving 
multicycle chemotherapy for the treatment of colorectal cancer. 
Using a randomized, placebo-controlled, dose-escalating study 
design, Meropol and colleagues conducted a multicenter trial 
to evaluate the efficacy of palifermin on attenuating ulcer-
ative mucositis in 81 patients receiving fluorouracil (FU) and 
leucovorin for the treatment of measurable metastatic colon 
or rectal adenocarcinoma.15 Subjects in the palifermin arm 
received three daily doses of the drug at one of six doses (range 
1 µg/kg to 80 µg/kg) three days before the infusion of FU. The 
authors reported that the incidence of ulcerative mucositis was 
reduced from 67% among those being treated with placebo to 
43% (not significant [NS]) in patients receiving any dose of 
palifermin. This trend was greatest for subjects receiving doses 
of palifermin 10 µg/kg. Although not significant, patient-
reported outcomes also tracked in favor of palifermin.
In a subsequent phase II study, Rosen and colleagues16 
reported the effect of palifermin on the incidence of oral 
mucositis in a prospective, randomized, double-blind, 
placebo-controlled trial of 64 subjects. In this multicenter trial, 
36 subjects were randomized to receive placebo. The remainder 
were treated with 40 µg/kg of palifermin for three consecutive 
days prior to infusion of FU and leucovorin. Patients were 
studied for two consecutive chemotherapy cycles. The authors 
reported that palifermin was superior to placebo in reducing 
the incidence of ulcerative mucositis (WHO grade 2) for 
both cycle 1 (palifermin 29% vs placebo 61%) and cycle 2 
(palifermin 11% vs 47% placebo). In addition, patients who 
were treated with palifermin in cycle 1 were less likely to 
require chemotherapy dose reductions in cycle 2 (31% placebo 
vs 14% palifermin). Patient reported mouth and throat soreness 
was also reduced by the administration of palifermin.
Early results of a multicenter, randomized, double-blind, 
placebo-controlled trial in which palifermin was studied for 
its ability to prevent mucositis in sarcoma patients receiv-
ing doxorubicin-based chemotherapy were favorable.17 
Forty-eight sarcoma patients received placebo or palifermin 
180 µg/kg as a single dose three days prior to chemotherapy in 
blinded fashion, or once a patient developed grade 3 mucositis, 
for up to six cycles of treatment. None of the subjects who 
received open-label palifermin (n = 7) developed WHO grade 
mucositis 3. The study is still being completed.
In an observational study of ten subjects treated at a single 
site with high-dose methotrexate18 palifermin at a dose of 
60 µg/kg administered for three days before and after (total 
six doses) methotrexate infusion reduced the maximum grade 
of oral mucositis in 10 patients who had previously experi-
enced WHO grade 3. Opioid use was also reduced.
Finally, a case report in which a patient undergoing 
polychemotherapy for the treatment of a high grade B cell 
lymphoma describes the efficacy of palifermin (60 µg/kg 
given three days before and three days after chemotherapy) in 
preventing mucositis in a female patient who was hospitalized 
for mucositis during prior chemotherapy cycles.19
Head and neck cancer
Mucositis is common and severe in patients receiving 
chemoradiation for the treatment of cancers of the mouth, 
oropharynx, larynx, and hypopharynx. In a multicenter, 
double-blind, randomized, placebo-controlled study Brizel 
and colleagues20 evaluated the efficacy of palifermin in 
modulating mucositis in 67 patients compared to a control 
cohort of 32 subjects. Patients in the active group received 
ten weekly doses of palifermin 60 µg/kg administered start-
ing on the Friday before the start of seven weeks of radiation 
therapy and continuing for two weeks after its completion. 
Subjects who received palifermin had a shorter duration of 
ulcerative mucositis (WHO grade 2) than did placebo-
treated patients (6.5 weeks vs 8.1 weeks; NS). Palifermin 
appeared to be more effective in patients being treated with 
hyperfractionated (1.25 Gy twice daily) radiation than those 
who received standard (2 Gy once day) therapy.
Results of a multicenter, randomized, placebo-controlled, 
double-blind trial of palifermin in patients with locally 
advanced head and neck cancer were reported by Le and 
colleagues.21 In this multinational study, half of the 188 
enrolled subjects received palifermin (180 µg/kg) in weekly 
doses throughout their treatment with conventional courses of 
chemoradiation (radiation 2 Gy/day). The remaining subjects 
were treated with placebo. Palifermin favorably affected the 
incidence of severe mucositis (active 54% vs placebo 69%; 
p = 0.041), median duration of severe mucositis (active 5 days 
vs placebo 26 days) and time to onset of severe mucositis 
(active 47 days vs 35 days for placebo).
Henke and colleagues22 reported the results of a 
multinational, multicenter, randomized, double-blind, 
placebo-controlled phase III study in which the efficacy of Core Evidence 2009:4 204
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palifermin was studied in 186 subjects also receiving a standard 
chemoradiation (2 Gy per day) dosing regimen. Active subjects 
were given 120 µg/kg of palifermin three days before the start 
of chemoradiation and then weekly throughout treatment. The 
incidence of severe mucositis was reduced in patients treated 
with palifermin (51%) compared to controls (67%; p = 0.027). 
Palifermin was also superior to placebo when median dura-
tion of severe oral mucositis (4.5 days vs 22 days) and time 
to onset were compared.
Economic evidence
Using data obtained from a phase III trial of palifermin in a 
212 subject HSCT cohort (see Spielberger and colleagues9), 
Elting and colleagues applied estimated costs of hospital stay 
from the National Inpatient Survey.23 The cost estimates, based 
on charges using Medicare’s state-specific cost-to-charge 
ratios were applied to study outcomes measures of incidence of 
febrile neutropenia, bacteremia/fungemia, pneumonia, and use 
of total parenteral nutrition. The mean cost of a hospital day in 
the HSCT population ranged from US$2,834 in the absence 
of adverse outcomes to US$4,663 when all of the above 
outcomes were present. Since administration of palifermin 
lowered the incidence of adverse outcomes, the savings 
achieved offset its price. An insignificant mean savings of 
US$3,595 per patient was associated with palifermin use.
Patient group/population
Data support the use of palifermin in patients with hemato-
logic malignancies who plan to receive mucotoxic condition-
ing regimens in preparation for HSCT.
Data supporting for the use of palifermin in the prevention 
of oral mucositis among patients being treated for carcinomas 
(colorectal or head and neck) is accumulating. Since this 
population constitutes the largest cohort of the mucositis 
at-risk population, the potential beneficial impact of an effec-
tive agent for mucosal protection is significant.
Assuming proof of efficacy, two barriers might impede the 
adoption of palifermin in this group: 1. palifermin is relatively 
expensive and cost-benefit will have to be demonstrated, 
especially in nonhead and neck cancer patients for whom 
the risk of significant mucositis is unpredictable and hovers 
around 20%–30% for the first cycle of chemotherapy; and 2. 
since epithelial tumors have receptors for KGF, some clini-
cians have voiced concern that palifermin has the potential to 
stimulate primary or secondary tumor growth. While there 
are no data to support this hypothesis, and xenograft models 
have demonstrated that palifermin neither stimulates tumor 
growth nor confers tumor protection from chemotherapy,24 
it is imperative that palifermin’s inertia relative to tumor 
behavior be confirmed if the agent is to be widely accepted 
by the clinical community.
Dosage, administration, 
and formulations
Palifermin (Kepivance®, Amgen/Biovitrum) is the 140 amino 
acid protein, human recombinant keratinocyte growth 
factor-1 (KGF-1), a member of the FGF super family. It is 
manufactured in Escherichia coli and supplied as a white, 
preservative-free, lyophilized powder that is reconstituted 
with sterile water for intravenous infusion. Kepivance® is dis-
pensed in single-use vials containing 6.25 mg of palifermin, 
50 mg of mannitol, 25 mg of sucrose, 1.94 mg of L-histidine, 
and 0.13 mg of polysorbate 20 (0.01%).
The following dosing information is quoted directly from 
the manufacturer’s instructions for use:
The recommended dosage of Kepivance® is 60 mcg/kg/day, 
administered as an IV bolus injection for three consecutive days 
before and three consecutive days after myelotoxic therapy for 
a total of six doses.
Pre-myelotoxic therapy
The first three doses should be administered prior to 
myelotoxic therapy, with the third dose 24 to 48 hours before 
myelotoxic therapy.
Post-myelotoxic therapy
The last three doses should be administered post-myelotoxic 
therapy; the first of these doses should be administered after, 
but on the same day of hematopoietic stem cell infusion 
and at least four days after the most recent administration 
Table 1 Evidence base included in the review
Category Number of records
  Full papers Abstracts
Initial search
  records excluded 88 1
  records included 11 3
Additional studies identified 0 0
Level 1 clinical evidence  0 0
Level 2 clinical evidence  4 3
Level  3 clinical evidence 5 0
  Trials other than rCT 1 0
  Case reports 1 0
Economic evidence 1 0
Notes: For definitions of levels of evidence see the Core Evidence website (http://www.
dovepress.com/core-evidence-journal).
Abbreviation: rCT, randomized controlled trial.Core Evidence 2009:4
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of Kepivance®. No dose adjustment is recommended for 
patients with renal impairment. Kepivance is only approved 
for use in patients with hematologic malignancies planned to 
receive conditioning regimens in preparation for HSCT.
Clinical value
Oral mucositis takes a significant toll on patients. Asked which 
toxicity of chemotherapy was most significant, patients who 
had received myeloablative chemotherapy or those receiving 
head and neck radiation placed mucositis at the top of their list. 
The lack of an effective agent to prevent and treat the condi-
tion has frustrated clinicians since the advent of cytotoxic 
cancer therapy. Palifermin is the first, mechanistically-based, 
approved intervention. Its efficacy in the HSCT population is 
proven. However, given the limited approved application of 
palifermin, its overall value has yet to be determined.
Disclosure
Dr Sonis has received a research grant from Amgen.
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